Cytosorbents Corporation (NASDAQ:CTSO) went down by -11.54% from its latest closing price compared to the recent 1-year high of $11.68. The company’s stock price has collected -23.18% of loss in the last five trading sessions. Press Release reported on 10/12/21 that CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Is It Worth Investing in Cytosorbents Corporation (NASDAQ :CTSO) Right Now?
Plus, the 36-month beta value for CTSO is at 0.38. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Cytosorbents Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $13.80. CTSO currently public float of 39.70M and currently shorts hold a 4.79% ratio of that float. Today, the average trading volume of CTSO was 247.58K shares.
CTSO’s Market Performance
CTSO stocks went down by -23.18% for the week, with a monthly drop of -26.32% and a quarterly performance of -20.08%, while its annual performance rate touched -30.89%. The volatility ratio for the week stands at 6.79% while the volatility levels for the past 30 days are set at 3.84% for Cytosorbents Corporation. The simple moving average for the period of the last 20 days is -23.11% for CTSO stocks with a simple moving average of -28.92% for the last 200 days.
Analysts’ Opinion of CTSO
Many brokerage firms have already submitted their reports for CTSO stocks, with Jefferies repeating the rating for CTSO by listing it as a “Buy.” The predicted price for CTSO in the upcoming period, according to Jefferies is $15 based on the research report published on September 17th of the previous year 2020.
SVB Leerink, on the other hand, stated in their research note that they expect to see CTSO reach a price target of $15. The rating they have provided for CTSO stocks is “Outperform” according to the report published on September 01st, 2020.
Maxim Group gave a rating of “Buy” to CTSO, setting the target price at $12 in the report published on August 08th of the previous year.
CTSO Trading at -25.46% from the 50-Day Moving Average
After a stumble in the market that brought CTSO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.54% of loss for the given period.
Volatility was left at 3.84%, however, over the last 30 days, the volatility rate increased by 6.79%, as shares sank -25.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.56% lower at present.
During the last 5 trading sessions, CTSO fell by -23.18%, which changed the moving average for the period of 200-days by -25.06% in comparison to the 20-day moving average, which settled at $7.87. In addition, Cytosorbents Corporation saw -23.09% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CTSO starting from Kraus Al, who sale 4,000 shares at the price of $9.40 back on Aug 31. After this action, Kraus Al now owns 125,046 shares of Cytosorbents Corporation, valued at $37,591 using the latest closing price.
Kraus Al, the Director of Cytosorbents Corporation, sale 8,000 shares at $8.00 during a trade that took place back on Nov 10, which means that Kraus Al is holding 125,046 shares at $64,000 based on the most recent closing price.
Stock Fundamentals for CTSO
Current profitability levels for the company are sitting at:
- -25.29 for the present operating margin
- +73.05 for the gross margin
The net margin for Cytosorbents Corporation stands at -19.11. The total capital return value is set at -20.79, while invested capital returns managed to touch -16.12. Equity return is now at value -13.30, with -10.90 for asset returns.
Based on Cytosorbents Corporation (CTSO), the company’s capital structure generated 1.30 points at debt to equity in total, while total debt to capital is 1.28. Total debt to assets is 1.14, with long-term debt to equity ratio resting at 0.73. Finally, the long-term debt to capital ratio is 0.72.
When we switch over and look at the enterprise to sales, we see a ratio of 5.83, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 8.52 and the total asset turnover is 0.70. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.12.